http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2010136974-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-94 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-33 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate | 2009-03-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2012-03-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2010136974-A |
| titleOfInvention | METHODS FOR TREATING INFLAMMATORY PAIN |
| abstract | 1. The use of antibodies to the CGRP antagonist to obtain drugs for the prevention and / or treatment of inflammatory pain and / or symptoms of inflammatory pain. ! 2. The use according to claim 1, where the drug is obtained for peripheral administration. ! 3. The use according to claim 1, where the drug is administered peripherally. ! 4. The use according to claim 1, where the drug is obtained for oral, sublingual, inhalation, transdermal, subcutaneous, intravenous, intraarterial, intraarticular, periarticular, local and / or intramuscular administration. ! 5. The use according to claim 4, where the drug is obtained for subcutaneous or intravenous administration. ! 6. The use according to claim 1, where the antibody to the CGRP antagonist upon administration acts peripherally. ! 7. The use according to claim 1, where the inflammatory pain is pain with arthritis. ! 8. The use according to claim 7, where the pain with arthritis is pain with osteoarthritis. ! 9. The use according to claim 1, where the antibody to the CGRP antagonist:! (a) binds to CGRP; ! (b) blocks the binding of CGRP to its receptor; ! (c) blocks or decreases activation of the CGRP receptor; ! (d) inhibits, blocks, inhibits or reduces the biological activity of CGRP; ! (e) increases the clearance of CGRP; and / or! (g) inhibits the synthesis, production, or secretion of CGRP. ! 10. The use according to claim 1, where the antibody to the CGRP antagonist:! (i) is a human antibody,! (ii) is a humanized antibody,! (iii) is a monoclonal antibody,! (iv) binds CGRP with a Kd of 50 nM or less (as measured by surface plasma resonance at 37 ° C); and / or! (v) has an in vivo half-life of at least 7 days. ! 11. The use according to claim 1, where |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2535095-C2 |
| priorityDate | 2008-03-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 257.